Drug profile · INN
lasmiditan succinate
REYVOW
lasmiditan succinate (REYVOW) is a serotonin 1f (5-ht1f) receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — lasmiditan succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lasmiditan succinate (REYVOW) is a serotonin 1f (5-ht1f) receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 1f (5-HT1f) receptor agonist
Primary target: 5-hydroxytryptamine receptor 1F
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lasmiditan succinate?
lasmiditan succinate (REYVOW) is a serotonin 1f (5-ht1f) receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lasmiditan succinate?
REYVOW is a marketed brand name for lasmiditan succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lasmiditan succinate?
lasmiditan succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.